Open AccessIdentification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine
Author(s) -
Na Li,
Xianquan Zhan
Publication year - 2020
Publication title -
the epma journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.177
H-Index - 34
eISSN - 1878-5085
pISSN - 1878-5077
DOI - 10.1007/s13167-020-00220-3
Subject(s) - lung cancer , context (archaeology) , adenocarcinoma , personalized medicine , treatment of lung cancer , cancer , biology , medicine , cancer research , oncology , bioinformatics , computational biology , paleontology
Lung cancer is the most common malignant tumor with high morbidity (11.6% of the total diagnosed cancer cases) and mortality (18.4% of the total cancer deaths), and its 5-year survival rate is very low (20%). Clarification of any molecular events and the discovery of effective biomarkers will offer increasing promise for lung canner management. N 6 -methyladenosine (m 6 A) modification is one of the important RNA modifications that are closely associated with lung cancer, and are tightly regulated by m 6 A regulators. Elucidation of pathology-specific m 6 A regulators will directly contribute to lung cancer medical services in the context of predictive, preventive, and personalized medicine (PPPM).